Price History

Hover for the daily close. The dotted line marks the period open.

Compare DMAC with… →

DMAC Key Statistics

As of Sep 4, 2026

Trading

Open: $6.56
Previous Close: $6.56
Day's Range: 6.49–6.89
52-Week Range: 5.25–10.42
Volume: 189.50K
Beta: 0.97

Valuation

Market Cap: $364.00M
P/E Ratio: unprofitable
EPS (ttm): −0.74

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$32.77M
Profit margin: 0.00%
Shares Outstanding: 53.93M
1-Year Return: +25.70%

Dividend and dates

Earnings Date: November 11, 2026estimated
Avg Volume: 192.61K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DMAC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+127.69%−63.21%−15.20%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−15.20%
2025	+46.59%
2024	+91.20%
2023	+79.74%
2022	−57.64%
2021	−63.21%
2020	+109.07%
2019	+66.67%
2018	−41.80%
2017	+127.69%
2016 (partial year)	−38.93%

As of September 4, 2026.

DMAC Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$32.77M	—
2024	$0.00	−$24.44M	—
2023	$0.00	−$19.38M	—
2022	$0.00	−$13.68M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$34.40M	−$32.77M	—
2024	$0.00	—	−$26.68M	−$24.44M	—
2023	$0.00	—	−$21.27M	−$19.38M	—
2022	$0.00	—	−$14.00M	−$13.68M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DMAC Valuation vs Biotechnology Median

Median of 656 stocks

Metric	DMAC	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

DiaMedica Therapeutics Inc. (DMAC) carries a market capitalisation of $364.00M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 35 employees.

The most recent close on file for DMAC is $6.75, dated September 4, 2026. That is +$0.19 (+2.90%) against the previous close. The 52-week range on file runs from $5.25 to $10.42. The latest close sits 28.69% above that 52-week low.

Financial Health

In fiscal 2025, DiaMedica Therapeutics Inc. reported revenue of $0.00. The same year closed with a net loss of $32.77M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.74.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +25.70%. Measured over 10 years, that is +5.52% a year compounded. Beta against the wider market is reported at 0.97. Annualized volatility over the trailing 10 years is 86.1%.

Growth & Income

No dividend is on file for DMAC.

So far in 2026 the price is −15.20%. The strongest complete calendar year on file is 2017 at +127.69%; the weakest is 2021 at −63.21%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

DiaMedica Therapeutics Inc. (DMAC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
DiaMedica Therapeutics Inc.	DMAC	$364.00M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. DiaMedica Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Visit website →

DiaMedica Therapeutics Inc. (DMAC) Stock Analysis